EP. 1: Optimizing Care for Patients With Hepatocellular CarcinomaByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 2: Hepatocellular Carcinoma Risk Stratification and TherapyByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 3: Testing for Targetable Mutations in Hepatocellular CarcinomaByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 4: Targeting the VEGF Pathway in Hepatocellular CarcinomaByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 5: HCC: VEGF TKI Data and Treatment SelectionByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 6: PD-1/PD-L1 Antibodies and VEGF Inhibitors in HCCByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 7: Atezolizumab/Bevacizumab Data in Frontline HCCByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 8: Atezolizumab/Bevacizumab for HCC: Toxicity ManagementByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 9: Choosing Between VEGF TKIs for Frontline HCC TreatmentByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 10: HCC Treatment After Previous I/O TherapyByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 11: Novel Combinations Under Study for HCCByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021
EP. 12: Exciting Targets Under Study in HCCByTargeted OncologyPublished: November 5th 2020 | Updated: April 27th 2021